Ingredients: Analysis of active ingredients, intermediates, and excipients in pharmaceutical development and manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Ingredients
Trends, market analysis, and market growth reports on pharmaceutical ingredient suppliers and manufacturers. Sourcing and supply of active pharmaceutical ingredients (APIs), intermediates, excipients.
1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556
Next »

AstraZeneca Announces Jobs Cuts and R&D Restructuring

February 4, 2010
By:Patricia Van Arnum
ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca announced this week that it plans to undertake further restructuring in its research and development operations, resulting in the elimination of 3500 jobs.

Pfizer Streamlines and Prioritizes Pipeline

February 4, 2010
By:Erik Greb
ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer's first updated pipeline since its acquisition of Wyeth includes fewer projects than before and is targeted to specific diseases.

Week of Feb. 1, 2010: Company and People Notes: Cephalon Buys Mepha; BASi's CEO Retires; and More.

February 4, 2010
ePT--the Electronic Newsletter of Pharmaceutical Technology

Cephalon Buys Mepha; BASi's CEO Retires; and More.

Specialty Pharmaceutical Focus: Pancreatic Enzyme Products

February 2, 2010
By:Patricia Van Arnum
Pharmaceutical Technology

A look at the formulation challenges in pancreatic enzyme products.

Is the Internet to Blame for Unsafe Drug Use?

February 2, 2010
By:Angie Drakulich
Pharmaceutical Technology

FDA impersonators and counterfeit drugs threaten the public's trust in online pharmacies.

Do Visible Residue Limits Make the 10-ppm Carryover Limit Obsolete?

February 2, 2010
By:Richard J. Forsyth
Pharmaceutical Technology

The author discusses how the use of a visible residue limit has made the 10-ppm cleaning limit obsolete in many applications.

Innovation Today, Rewards Tomorrow

February 2, 2010
By:Billy Tauzin
Pharmaceutical Technology

When it comes to healthcare rform, we must not overlook investment in innovative technologies.

Advances in Custuom Synthesis

February 2, 2010
By:Patricia Van Arnum
Pharmaceutical Technology

As contract manufacturers and drug companies meet at Informex, the stage is set for the latest in pharmaceutical chemical development.

Science and Sensibility

February 2, 2010
By:Michelle Hoffman
Pharmaceutical Technology

The death of a pioneer in molecular genetics recalls age-old questions about social fitness to ensure the ethical uses of scientific advances.

1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556
Next »

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
13%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
23%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
FindPharma Custom Search
Featured Jobs

More Jobs

Click here